Clinical stage II seminoma: management options
| Autor: | Siamak Daneshmand, Muhannad Alsyouf |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Nephrology
Male medicine.medical_specialty Chemotherapy business.industry Urology General surgery medicine.medical_treatment Seminoma Neoplasms Germ Cell and Embryonal medicine.disease Primary cancer Radiation therapy Stage II Seminoma Retroperitoneal lymph node dissection Testicular Neoplasms Internal medicine medicine Humans Lymph Node Excision Retroperitoneal Space business Testis neoplasm Neoplasm Staging |
| Zdroj: | World journal of urology. 40(2) |
| ISSN: | 1433-8726 |
| Popis: | Introduction The management of clinical stage II seminoma has evolved with a recent emphasis on minimizing long-term morbidity while achieving oncologic cure. Methods In this review we discuss the available management options for clinical stage II seminoma with an emphasis on the emerging role of surgery in this patient population. Results Historically, treatment options available to clinical stage II seminoma patients were limited to radiotherapy and chemotherapy. Survival rates with these options are excellent; however, both are associated with significant long-term morbidities including cardiovascular, pulmonary, and neurologic toxicities. Additionally, higher rates of secondary malignancies are witnessed in this young patient population, decades after successful treatment of the primary cancer. Recently, retroperitoneal lymph node dissection has been proposed as a first-line treatment option for patients with low-volume metastatic seminoma. Conclusion The SEMS and PRIMETEST trials are two studies examining the role of primary retroperitoneal lymph node dissection in clinical stage II seminoma, and early data show significant promise. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink